About Persevere Therapeutics
We aspire to give every patient the best possible chance to live a healthy and cancer free life. Our clinical-stage drug misetionamide is bringing new hope to the fight against cancer through truly novel science.
Who We Are
We are focused on giving every patient the best possible outcome. Our clinical-stage drug misetionamide is bringing new hope to the fight against cancer through truly novel science.
Who We Are
Persevere Therapeutics is a privately held, clinical-stage pharmaceutical company developing a novel oncology asset, misetionamide (also known as GP-2250). Persevere, a US Delaware company located in Chesterbrook, PA, was founded in 2025 to focus on misetionamide and the oncology business. Persevere acquired all the intellectual property and development program of Geistlich Pharma and Panavance Therapeutics’ misetionamide program in 2026.
Misetionamide is a broadly active small molecule with a novel mechanism of action that inhibits two oncogenic transcription factors, c-MYC and NFκB. Acting through c-MYC, misetionamide selectively disrupts the energy metabolism of cancer cells leading to cancer cell death. Through NFκB inhibition, misetionamide inhibits cancer cells’ ability to proliferate and survive. This dual target mechanism makes misetionamide an attractive tumor cell selective agent.
Persevere has concluded a successful Phase 1 clinical trial in 56 cancer patients in 2025. The company plans to initiate a Phase 1b/2a clinical trial of misetionamide for the treatment of platinum-resistant ovarian cancer. Extensive preclinical studies have demonstrated that misetionamide’s broadly anti-neoplastic MOA has the potential to be effective in additional tumor types, including pancreatic, melanoma, squamous cell, breast, and colorectal cancers.
Why We Exist
We get up every morning with a clear focus on making a significant improvement in clinical outcomes and the lives of cancer patients everywhere. Like the mechanism of misetionamide, our mission is to disrupt cancer’s energy.
What We Deliver
Our clinical stage asset, misetionamide, has the potential to make a meaningful impact across many cancer types and therapeutic applications by targeting the primary sources of cancer cell energy production, proliferation, and survival with its unique mechanism of action.
What’s In A Name?
Why We’re Persevere.
We believe that our highly tumor cell selective asset may offer a broad benefit across and beyond cancers and in combination with existing treatments.
Misetionamide has broad therapeutic potential across stages of disease including neoadjuvant, adjuvant and advanced/metastatic disease.
We are dedicated to advancing innovative treatments and committed to improving outcomes for cancer patients worldwide. Patients must persevere everyday in the battle against this disease.
Science
Discover our novel mechanism of action.
Our mechanism of action suppresses cancers by disrupting their energy metabolism, bringing about cancer cell death.